Summary
A spectrum of adverse drug reactions that are caused by the combined action of drugs and viruses has been described: ampicillin rash in acute infectious mononucleosis; Reye’s syndrome; hypersensitivity reactions to sulphonamides in patients with HIV infection; drug-induced agranulocytosis; paracetamol (acetaminophen) hepatotoxicity; aspirin (acetylsalicyclic acid)-induced asthma; Epstein-Barr virus-associated lymphoma and methotrexate; and AIDS-related Kaposi’s sarcoma and nitrite use.
Changes in pharmacokinetics have been reported for: caffeine, sulfamethoxazole and fluconazole in patients with HIV infection; theophylline, following influenza and influenza vaccination; and recently, dipyrone metabolites in carriers of the hepatitis B virus. In addition increased drug- and drug metabolite-related toxicity has been observed in virally infected cells.
Pathogenetic mechanisms for the interaction between drugs and viruses are varied, and include biological mechanisms (often immunological) and changes in drug metabolism. The combined effects of chemical and biological exposure provide a unique model for the study of disease induction.
Similar content being viewed by others
References
Evans ES. The clinical illness promotion factor — a third ingredient. Yale J Biol Med 1982; 55: 193–9
Levy M. The combined effect of viruses and drugs in drug-induced diseases. Med Hypotheses 1984; 14: 293–6
Haverkos HW, Amsel Z, Drotman DP. Adverse virus-drug interactions. Rev Infect Dis 1991; 13: 697–704
Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; II: 1176–8
McKenzie H, Parratt D, White RG. IgM and IgG antibody levels to ampicillin in patients with infectious mononucleosis. Clin Exp Immunol 1976; 26: 214–21
Williams RC, Kenyon AJ, Huntley CC. Immunoglobulins, viruses and speculation on their interrelationship in certain human and animal disease states. Blood 1968; 31: 522–35
Nazareth I, Mortimer P, McKendrick GD. Ampicillin sensitivity in infectious mononucleosis-temporary or permanent?. Scand J Infect Dis 1972; 4: 229–31
Report of a collaborative study group: a prospective study of ampicillin rash. BMJ 1973; 1: 7–9
Gregg I. Ampicillin rash and influenza [letter]. BMJ 1973; 1: 295
Reye RDK, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera: a disease entity of childhood. Lancet 1963; II: 749–52
Starko KM, Ray CG, Dominguez LB, et al. Reye’s syndrome and salicylate use. Pediatrics 1980; 66: 859–64
Waldman RJ, Hall WN, McGee H, et al. Aspirin as a risk factor in Reye’s syndrome. JAMA 1982; 274: 3089–94
Maheady DC. Reye’s syndrome: review and update. J Pediatr Health Care 1989; 3: 246–50
Hurwitz ES. The changing epidemiology of Reye’s syndrome in the United States: further evidence of a public health success. JAMA 1988; 260: 3178–80
Peters LJ, Wiener GJ, Gilliam J, et al. Reye’s Syndrome in adults, a case report and review of the literature. Arch Intern Med 1986; 146: 2401–3
Gordin FM, Simons GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495–9
Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim -sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776–82
Jaffe HS, Abrams DI, Amman AJ, et al. Complications of cotrimoxazole of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; II: 1109–11
Van der Ven AJAM, Koopmans PP, Vree TB, et al. Adverse reactions to co-trimethoxazole in HIV infection. Lancet 1991; 338:431–3
Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522–6
Carr A, Swandson C, Penny R, et al. Clinical and laboratory markers of hypersensitivity to trimethoprim/sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167: 180–5
Ackerman Z, Levy M. Hypersensitivity reactions to drugs in acquired immunodeficiency syndrome. Postgrad Med J 1987; 63: 55–6
Coopman MA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670–4
Havercos HW, Pinsky PF, Drotman DP, et al. Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi’s sarcoma. Sex Transm Dis 1985; 12: 203–8
Archibald CP, Schechter MT, Le TN, et al. Evidence of a sexually transmitted cofactor for AIDS-related Kaposi’s sarcoma in a cohort of homosexual men. Epidemiology 1992; 3:203–9
Haverkos HW, Kopstein AN, Wilson H, et al. Nitrite inhalants: history, epidemiology and possible links to AIDS. Environ Health Perspect 1994; 102: 858–61
Mirvish SS, Williamson J, Babcook D, et al. Mutagenicity of iso-butyl nitrite vapor in the Ames test and some relevant chemical properties, including the reaction of iso-butyl nitrite with phosphate. Environ Mol Mutagen 1993; 21: 247–52
Macdonald MG, McGrath PP, McMartin DN. Potentiation of the toxic effects of acetaminophen in mice by concurrent infection with influenza B virus: a possible mechanism for human Reye’s syndrome. Pediatr Res 1984; 18: 181–7
Renton KW, Dickson G. The prevention of acetaminophen-induced hepatotoxicity by the interferon inducer poly (r 1. r C). Toxicol Appl Pharmacol 1984: 72: 40–5
Rosenberg DM, Meyer AA, Manning IH, et al. Acetaminophen and hepatic dysfunction in infectious mononucleosis. South Med J 1977; 70: 660–1
Ackerman Z, Flugelman MY, Wax Y, et al. Hepatitis during measles in young adults: possible role of antipyretic drugs. Hepatology 1989; 10: 203–6
Kaufman DW, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991
Levy M, Kelly JP, Kaufman DW, et al. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the International Agranulocytosis and Aplastic Anemia Study. Ann Hematol 1993; 67: 187–90
Purtilo DT. Epstein-Barr virus: the spectrum of its manifestations in human beings. South Med J 1987; 80: 943–7
Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18: 15–20
Kamel OW, Van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317–21
Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988; 15: 396–420
McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42–69
Joanne C, Paintaud G, Bresson-Hadni S, et al. Is debrisoquine hydroxylation modified during acute viral hepatitis?. Fundam Clin Pharmacol 1994; 8: 76–9
Lee BL, Wong D, Benowitz NL, et al. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529–35
Dolomenie C, Grant DM, Mathelier-Fusade P, et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994; 38: 581–2
Kaufman GR, Wenk M, Taeschner W, et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60: 62–7
Singh G, Renton KW. Interferon-mediated depression of cytochrome P-450 dependent drug biotransformation. Mol Pharmacol 1981; 20: 681–4
Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious diseases. Can J Physiol Pharmacol 1990; 68: 777–81
Ghezzi P, Bianchi M, Gianera L, et al. Role of reactive oxygen intermediates in the interferon-mediated depression of hepatic drug metabolism and protective effect of N-acetylcysteine in mice. Cancer Res 1985; 45: 3444–7
Proulx M, du Souich P. Inflammation-induced decrease in hepatic cytochrome P450 in conscious rabbits is accompanied by an increase in hepatic oxidative stress. Res Commun Mol Pathol Pharmacol 1995; 87: 221–36
Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13–7
Carr A, Gross AS, Hoskins JM, et al. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim sulphamethoxazole in HIV-infected patients. AIDS 1994; 8: 333–7
Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179–87
Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-sero-positive individuals. Lancet 1989; II: 1294–8
Van der Ven AJAM, Vree TB, Van Ewijk-Beneken Kolmer EWJ, et al. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmacol 1995; 39: 621–5
Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro ‘rechallenge’ with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286–9
Carr A, Tindall B, Penny R, et al. In vitro cytotoxicity as a marker of cytotoxicity to sulphamethoxazole in patients with human immunodeficiency virus (HIV) infection. Clin Exp Immunol 1993; 94: 21–5
DeMuria D, Forrest A, Rich J, et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2187–92
Yeates RAM, Rahnke Y, Pfau SA, et al. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. Br J Clin Pharmacol 1994; 38: 77–9
Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother 1995; 39: 1835–41
Gatti G, Flaherty J, Bubp J, et al. Comparative study of bioavailability and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993; 37: 1137–43
Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995; 28: 216–34
Levy M, Leibowitz Y, Ilan Y, et al. Dipyrone metabolites kinetics in carriers of hepatitis B virus with normal liver function tests: preliminary results [abstract]. Therapie 1995; Suppl.: 482
Svensson CK, Knowlton PW. Effect of the immunomodulator tilorone on the in vivo acetylation of procainamide in the rat. Pharm Res 1989; 6: 477–80
Kramer P, McClain C. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262–4
Chang CK, Lauer BA, Bell TD, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; I: 1132–3
Kraemer MJ, Furukawa CT, Coup J, et al. Altered theophylline clearance during an influenza B outbreak. Paediatrics 1982; 69: 476–80
Renton KW. Theophylline pharmacokinetics in respiratory viral illness. Lancet 1978; II: 160–1
Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1980; 125: 288–90
Walker S, Schreiber L, Middelkamp C. Serum theophylline levels after influenza vaccination. Can Med Assoc J 1981; 125: 243–4
Meredith CG, Christian CD, Johnson RF, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 1985; 37: 396–401
Goldstein RS, Cheung OT, Seguin R, et al. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1982; 126:470
San Joaquin VH, Reyes S, Marks MI. Influenza vaccination in asthmatic children on maintenance theophylline therapy. Clin Pediatr 1982; 21: 724–6
Fischer RG, Booth BJ, Mitchell DQ, et al. Influence of trivalent influenza vaccine on serum theophylline levels. Can Med Assoc J 1982; 126: 1312–3
Grabowski N, May JJ, Prett DS. No effect of split virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1985; 131:934–8
Kortabarria R, Duran JA, Abadin JA, et al. Influenza vaccination and plasma concentrations of theophylline in patients with asthma and COPD. Clin Drug Invest 1995; 9: 161–5
Hannan SE, May JJ, Pratt DS, et al. The effect of whole virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1988; 137: 903–6
Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262–4
Kramer P, Tsuru M, Cook CE, et al. Effects of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35: 416–8
Lipsky BA, Pecoraro NJ, Roben NJ, et al. The effect of the influenza vaccination (IV) on warfarin anticoagulation. Ann Intern Med 1984; 100: 835–7
Rieder Ml, Bird IA, Dekaban GA. Kinetics of increased sensitivity to sulfonamide reactive metabolites in HIV-infected cells [abstract]. Clin Pharmacol Ther 1995; 57: 135
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, M. Role of Viral Infections in the Induction of Adverse Drug Reactions. Drug-Safety 16, 1–8 (1997). https://doi.org/10.2165/00002018-199716010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199716010-00001